Vertex says telaprevir may cut down HCV treatment time

08/11/2010 | Google

Some hepatitis C patients who took drug candidate telaprevir were able to finish treatment sooner than with standard therapy, according to Vertex Pharmaceuticals. The company said patients in the clinical trial who responded quickly to telaprevir had better results after 24 weeks of therapy compared with 48 weeks.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC